Prometheus takes on Pfizer in inflammatory bowel diseases

When biotechs square up to big pharma it does not always end well for the minnows. But investors in Prometheus Biosciences clearly believe that this time it will be different, with the group seeing its stock climb steadily over the summer.

The optimism has been spurred by positive comments from Pfizer on its anti-TL1A antibody, PF-06480605 – Prometheus’s lead project, PRA023, has the same mechanism of action. Data due soon could shed light on whether the smaller group has, as it hopes, the more effective agent.